Clinical trial shows that solanezumab, an antibody-based treatment for Alzheimer’s disease, does not significantly slow cognitive decline.
Columbia scientists observed how molecules that regulate chemical signaling in the brain interact with the AMPA receptor, governing brain function.
Columbia researchers have linked excess tau protein in the brain to the spatial disorientation that leads to wandering in many Alzheimer's disease patients.
Researchers found an odor identification test useful in predicting cognitive decline and detecting early-stage Alzheimer’s disease.
A toxic Alzheimer's protein can spread through the brain via the extracellular space that surrounds the brain's neurons, suggests research from Columbia University Medical Center.
In honor of the ADRC's anniversary, Columbia scientists discussed breakthroughs in Alzheimer's disease research with an eye to future therapies.